See more : HOTMAN Co.,Ltd. (3190.T) Income Statement Analysis – Financial Results
Complete financial analysis of Oncology Pharma Inc. (ONPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncology Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Booking Holdings Inc. (BKNG) Income Statement Analysis – Financial Results
- Amtech Systems, Inc. (ASYS) Income Statement Analysis – Financial Results
- Shalibhadra Finance Limited (SAHLIBHFI.BO) Income Statement Analysis – Financial Results
- CRH plc (CRH) Income Statement Analysis – Financial Results
- China Qinfa Group Limited (0866.HK) Income Statement Analysis – Financial Results
Oncology Pharma Inc. (ONPH)
About Oncology Pharma Inc.
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18M | 3.28M | 3.67M | 4.01M | 993.40K | 892.19K | 1.27M | 1.03M |
| Cost of Revenue | 0.00 | 0.00 | 779.00 | 1.11K | 1.11K | 654.00K | 1.21M | 1.36M | 1.34M | 321.60K | 624.82K | 837.13K | 554.03K |
| Gross Profit | 0.00 | 0.00 | -779.00 | -1.11K | -1.11K | 527.00K | 2.07M | 2.31M | 2.68M | 671.80K | 267.38K | 437.48K | 477.82K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 44.62% | 63.05% | 63.02% | 66.68% | 67.63% | 29.97% | 34.32% | 46.31% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 376.00K | 780.00K | 773.00K | 954.18K | 1.18M | 407.48K | 364.54K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 62.05K | 14.41M | 402.77K | 817.76K | 1.85M | 2.91M | 3.56M | 3.08M | 3.83M | 2.34M | 2.91M | 3.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 62.05K | 14.41M | 402.77K | 817.76K | 2.23M | 3.69M | 4.33M | 4.24M | 5.42M | 2.75M | 3.28M | 3.23M |
| Cost & Expenses | 0.00 | 62.05K | 14.41M | 403.88K | 818.86K | 2.88M | 4.91M | 5.69M | 5.57M | 5.74M | 3.38M | 4.11M | 3.78M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 0.00 | 86.00K | 243.24K | 242.81K | 0.00 | 98.24K | 0.00 |
| Interest Expense | 0.00 | 104.62M | 82.81M | 25.00K | 31.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 779.00 | 1.11K | 1.11K | 81.00K | 395.00K | 341.00K | 457.28K | 402.82K | 63.54K | 79.91K | 21.79K |
| EBITDA | 0.00 | -7.88K | -14.66M | -181.45K | -817.76K | -1.75M | -1.48M | -1.13M | -1.61M | -1.08M | -4.33M | -2.02M | -2.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -148.26% | -40.09% | -45.04% | -27.00% | -435.57% | -266.43% | -213.65% | -263.15% |
| Operating Income | 0.00 | -62.05K | -14.41M | -403.88K | -818.86K | -1.70M | -1.63M | -2.02M | -1.82M | -4.75M | -2.49M | -2.84M | -2.75M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -144.03% | -49.54% | -54.90% | -45.26% | -477.69% | -278.54% | -222.78% | -266.35% |
| Total Other Income/Expenses | 0.00 | -104.56M | -83.06M | 196.33K | -31.53K | 131.00K | 136.00K | 105.00K | -135.39K | 222.15K | 227.17K | 720.08K | -274.44K |
| Income Before Tax | 0.00 | -104.63M | -97.47M | -207.56K | -850.40K | -1.57M | -1.54M | -2.04M | -1.59M | -4.76M | -2.53M | -2.88M | -2.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -132.94% | -46.95% | -55.47% | -39.72% | -479.26% | -283.52% | -225.64% | -267.43% |
| Income Tax Expense | 0.00 | -236.56K | 3.49K | 1.00 | 1.00 | -136.00K | -105.00K | -65.00K | 31.75K | -227.17K | 25.73K | -61.78K | -36.67K |
| Net Income | 0.00 | -104.63M | -97.47M | -207.56K | -850.40K | -1.57M | -1.52M | -1.95M | -1.59M | -4.52M | -2.51M | -2.78M | -2.71M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -132.51% | -46.34% | -53.13% | -39.72% | -454.82% | -281.42% | -217.93% | -262.79% |
| EPS | 0.00 | -3.42 | -6.76 | -0.12 | -0.72 | -782.50K | -1.52M | -1.95M | -1.59M | -4.52M | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -3.42 | -6.76 | -0.12 | -0.72 | -782.50K | -1.52M | -1.95M | -1.59M | -4.52M | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 38.56M | 30.55M | 14.42M | 1.68M | 1.19M | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 38.56M | 30.55M | 14.42M | 1.68M | 1.19M | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of...
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is moving ahead with advancing its efforts with Ribera Solutions' Conect2Med platform with Oncology Pharma's exclusivity for oncology, including drug development,...
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize...
RGBP Stock: Why Little-Known Regen Biopharma Is Soaring 800% Today
Here's why RGBP stock is seeing massive gains today, following an annoucnement investors seem to be very bullish on. The post RGBP Stock: Why Little-Known Regen Biopharma Is Soaring 800% Today appeared first on InvestorPlace.
Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer
SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This...
Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
SAN FRANCISCO, CA, March 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has provided the initial financing for the initiation of formal drug development and preclinical planning; based upon...
Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company's plans for growth and development of its intellectual property and business model. Key focal points include expansion of its...
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
San Francisco, CA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic...
Oncology Pharma Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform
San Francisco, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including...
Source: https://incomestatements.info
Category: Stock Reports